isoxazoles has been researched along with melphalan in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greig, NH; Rapoport, SI; Smith, QR; Takada, Y; Vistica, DT | 1 |
| Chikhale, PJ; Killian, DM | 1 |
| Atadja, P; Garcia-Echeverria, C; Heider, U; Jensen, MR; Kaiser, M; Lamottke, B; Mieth, M; Quadt, C; Sezer, O; Türkmen, S; von Metzler, I | 1 |
| Houghton, PJ; Kang, M; Kurmashev, D; Kurmasheva, RT; Reynolds, CP; Smith, MA; Wu, J | 1 |
| Imano, M; Ishizaka, T; Maekawa, S; Nishida, S; Satou, T; Tabata, M; Takeda, T; Tateishi, K; Tsubaki, M; Tsurushima, K | 1 |
5 other study(ies) available for isoxazoles and melphalan
| Article | Year |
|---|---|
Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier.
Topics: 2-Naphthylamine; Amino Acid Transport Systems; Animals; Azaserine; Blood-Brain Barrier; Brain; Buthionine Sulfoximine; Carrier Proteins; Diazooxonorleucine; Isoxazoles; Male; Melphalan; Methionine Sulfoximine; Nitrogen Mustard Compounds; Rats; Rats, Inbred Strains | 1991 |
A bioreversible prodrug approach designed to shift mechanism of brain uptake for amino-acid-containing anticancer agents.
Topics: Amino Acid Transport Systems; Amino Acids; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Blood-Brain Barrier; Brain; Carrier Proteins; Chromatography, High Pressure Liquid; Drug Carriers; In Vitro Techniques; Isoxazoles; Male; Melphalan; Perfusion; Prodrugs; Radioactive Tracers; Rats; Rats, Sprague-Dawley; Verapamil | 2001 |
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Melphalan; Multiple Myeloma; Resorcinols | 2010 |
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Cisplatin; Female; Humans; Isoxazoles; Melphalan; Mice; Mice, SCID; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2018 |
Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Melphalan; Morpholines; Multiple Myeloma; Resorcinols; Signal Transduction; src-Family Kinases; Unfolded Protein Response | 2020 |